Associate

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, April 12, 2024
UCLA, Congress, Sale, European Patent Office, Rutgers University, Chronic obstructive pulmonary disease, Outline of health sciences, Alopecia areata, Eosinophilic bronchitis, Safety, Skin, Drug development, European Patent Convention, Research, EASI, MD, Trial of the century, COPD, KOL, ADS, DHODH, Patent, Data, Patient, Liver, Dupilumab, Translational medicine, International Examiner, Harvard Medical School, ASLN, TREK, AA, Associate, Clinical trial, Emergency medicine, EPO, SAN, Contract research organization, Pharmaceutical industry

Cash used in operations for the fourth quarter of 2023 was $7.6 million compared to $12.0 million in the same period in 2022.

Key Points: 
  • Cash used in operations for the fourth quarter of 2023 was $7.6 million compared to $12.0 million in the same period in 2022.
  • Research and development expenses were $9.6 million in the fourth quarter of 2023 compared to $10.7 million in the fourth quarter of 2022.
  • General and administrative expenses were $3.2 million in the fourth quarter of 2023 compared to $2.7 million in the fourth quarter of 2022.
  • Net loss attributable to stockholders for the fourth quarter of 2023 was $13.5 million compared to a net loss of $14.5 million for the fourth quarter of 2022.

Draganfly to Showcase Cutting-Edge Drone Technologies at XPONENTIAL 2024 in San Diego

Retrieved on: 
Thursday, April 11, 2024
Equity, Hearing, Safety, AI, Partnership, San Diego Convention Center, Artificial intelligence, Artificiality, Commander, Colonel, Panel, USAF, Intelligence, Associate, Letter

San Diego, CA., April 11, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer is pleased to announce its participation at XPONENTIAL 2024 at booth #3818 in San Diego, CA from April 22nd to April 25th.

Key Points: 
  • San Diego, CA., April 11, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer is pleased to announce its participation at XPONENTIAL 2024 at booth #3818 in San Diego, CA from April 22nd to April 25th.
  • The Starling X.2, a product developed in partnership with Promo Drone, will also be presented, offering a glimpse into the future of unmanned aerial communication systems.
  • “Draganfly is thrilled to be at the forefront of the evolving landscape of drone technology and artificial intelligence, as showcased at the Xponential conference,” said Cameron Chell, CEO of Draganfly.
  • “We’re proud to demonstrate the capabilities of our North American-made drone technologies at the San Diego Convention Center, signaling a showcase of our current achievements and a preview of exciting product developments yet to be announced.

Ora and Singapore Eye Research Institute Unveil Groundbreaking Partnership to Propel Ophthalmology Innovation Globally

Retrieved on: 
Thursday, May 2, 2024
Science, Biotechnology, Research, Pharmaceutical, Optical, General Health, Health, Clinical Trials, MD, Partnership, Quality assurance, SNEC, ChromeOS, Accreditation, Chandran, Eye, Toxicity, Associate, Ophthalmology

Ora, Inc. , the foremost global ophthalmology contract research organization (CRO), today announced a strategic, exclusive partnership with the Singapore Eye Research Institute (SERI), a world-renowned institution for cutting-edge eye research and ophthalmic preclinical studies.

Key Points: 
  • Ora, Inc. , the foremost global ophthalmology contract research organization (CRO), today announced a strategic, exclusive partnership with the Singapore Eye Research Institute (SERI), a world-renowned institution for cutting-edge eye research and ophthalmic preclinical studies.
  • This exclusive partnership marks a significant milestone in the ophthalmology research industry by combining the unparalleled clinical development expertise of Ora with the cutting-edge preclinical study capabilities of SERI.
  • Aimed at providing early-stage innovators around the world with comprehensive research support, this partnership is set to revolutionize the development of new ophthalmic therapies.
  • Ora and SERI both prioritize the assurance of data integrity, reinforcing the credibility and trustworthiness of the preclinical research conducted.

Monocle Emerges From Stealth, Launches AI Platform to Power Promotion Strategies for Consumer Brands

Retrieved on: 
Thursday, May 2, 2024
Marketing, Advertising, Communications, Technology, Software, Other Communications, Artificial Intelligence, DTC, Investment, AI, Partnership, Entrepreneurship, Data science, General partnership, Associate, Death Wish Coffee, Stripe, Renewable energy

Monocle , an AI-powered promotion platform, today is emerging from stealth mode with technology to help consumer brands seamlessly deploy and personalize promotions to turn their spend into profit.

Key Points: 
  • Monocle , an AI-powered promotion platform, today is emerging from stealth mode with technology to help consumer brands seamlessly deploy and personalize promotions to turn their spend into profit.
  • Until now, only large consumer tech platforms had the resources and know-how to automate the process with causal based AI methods.
  • Monocle opened its platform to select brands in 2023, and is already being used by Death Wish Coffee, BRUNT Workwear, and Honeylove, among others.
  • “Throughout our years at big consumer technology companies, we recognized the power causal based AI models hold in driving successful incentive strategies,” says Noam Szpiro, Co-Founder and CEO of Monocle.

Kaplan Educational Foundation Honors Danielle Conley and Harold Elish for Commitment to Equity and Opportunity

Retrieved on: 
Wednesday, May 1, 2024
Professional Services, Philanthropy, DEI (Diversity, Equity and Inclusion), Other Education, Continuing, Fund Raising, University, Foundation, Primary, Secondary, Education, Yale University, Treasurer, Woman, LLP, Lawyer, Mentorship, Policy, Supreme court, HR, School, Award, Barack Obama, WEB, Justice, Reproductive rights, Financial Times, UBS, K-8, Supreme, LGBTQ, Engineering, Cornell University, Smith, Medicine, Committee, Multimedia, Graham Holdings, Democracy, Student, Associate, Government, Latham & Watkins, Management

View the full release here: https://www.businesswire.com/news/home/20240501978493/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240501978493/en/
    Kaplan Educational Foundation 2024 Leadership Award honorees Danielle Conley & Harold Elish (Photo: Business Wire)
    Ms. Conley and Mr. Elish will accept the Leadership Awards at the Foundation’s annual benefit on May 15th in New York City.
  • The Award recognizes a demonstrated commitment to increasing opportunity and equity for individuals who have been overlooked and underserved, in education and beyond.
  • She has significant experience conducting sensitive internal investigations on issues pertaining to racial and gender equity.
  • Mr. Elish joined the Board of the Kaplan Educational Foundation in 2014, becoming the first person unaffiliated with Kaplan to serve.

Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer

Retrieved on: 
Wednesday, May 1, 2024
Health, Technology, Health Technology, Artificial Intelligence, Oncology, Jane, Risk, American Urological Association, Recurrence, BCG, Docetaxel, CHAI, Data, University, Patient, Histology, Physician, AUA, Multimedia, Toxicity, Biomarker, Neoplasm, Associate, Medicine, Bladder cancer, Labs, Medical imaging

The biomarkers were successfully validated across 1000+ patients and 12 centers on four end-points, making it the largest validation study of its kind in bladder cancer.

Key Points: 
  • The biomarkers were successfully validated across 1000+ patients and 12 centers on four end-points, making it the largest validation study of its kind in bladder cancer.
  • View the full release here: https://www.businesswire.com/news/home/20240501832149/en/
    The CHAI biomarkers offer independent prognostic capabilities for high-grade recurrence and muscle-invasive progression in bladder cancer.
  • Validated across more than 1,000 patients and 12 centers, these biomarkers, available through the Vesta test, can enhance first-line treatment decision-making for non-muscle invasive bladder cancer.
  • We are able to visualize these biomarkers and gain a better understanding of how tumor morphology correlates to treatment response.”

UMC Introduces Industry’s First 3D IC Solution for RFSOI, Accelerating Innovations in the 5G Era

Retrieved on: 
Thursday, May 2, 2024
Semiconductor, IOT (Internet of Things), Satellite, Technology, Mobile, Wireless, 5G, Hardware, Virtual reality, Internet of things, Gallium nitride, Research, Silicon, Gallium arsenide, Wi-Fi, 3D, UMC, 3D IC, RF, Multimedia, United Microelectronics Corporation, Associate, Mobile phone

United Microelectronics Corporation (NYSE: UMC; TWSE: 2303) (“UMC”), a leading global semiconductor foundry, today announced the industry’s first 3D IC solution for RFSOI technology.

Key Points: 
  • United Microelectronics Corporation (NYSE: UMC; TWSE: 2303) (“UMC”), a leading global semiconductor foundry, today announced the industry’s first 3D IC solution for RFSOI technology.
  • RFSOI is the foundry process used for RF chips such as low noise amplifiers, switches, and antenna tuners.
  • Utilizing wafer-to-wafer bonding technology, UMC’s 3D IC solution for RFSOI resolves the common issue of RF interference between stacked dies.
  • “We are proud to lead the industry in offering this state-of-the-art solution utilizing our innovative 3D IC technology for RF-FEM.

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

Retrieved on: 
Wednesday, May 1, 2024
Optical, Health, Surgery, Medical Devices, Corporation, Science, Medtech, Near-sightedness, Law, University, Presbyopia, American Tower, Believer, EVO, General counsel, OTC, Marketing, Commerce, Johnson & Johnson, STAAR, Surgeon, University School, Business, Partner (business rank), CareFusion, Contact, Duke University, NuVasive, Senior, Patient, Multimedia, Global marketing, Emory University, Associate, Astigmatism, Economics, Nate, Growth, Engineering, Management

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.
  • View the full release here: https://www.businesswire.com/news/home/20240501408389/en/
    “We are thrilled to strengthen the STAAR team with the addition of Nancy and Nate, two seasoned executives with extensive senior leadership experience.
  • “Nancy is a perfect fit for the newly created Chief Marketing Officer position and will be critical to driving our brand awareness and innovation globally.
  • “I am thrilled to join the STAAR leadership team at a time of significant opportunity and growth for our vision correction lenses,” said Nate Sisitsky.

Prime Coalition and Rho Impact Unveil New Open-Access Tool to Assess Impact Potential of Climate Technologies

Retrieved on: 
Wednesday, May 1, 2024
Environment, Climate Change, Finance, Professional Services, Philanthropy, Green Technology, Fund Raising, Other Philanthropy, Foundation, Climate change, Incubator, Investment, Harvard University endowment, Climate, Software, Partnership, Aggregation, Stanford University, Government, Multimedia, Associate, SFCW, Management

Prime Coalition and Rho Impact unveiled the new CRANE tool during a San Francisco Climate Week (SFCW) panel discussion last week.

Key Points: 
  • Prime Coalition and Rho Impact unveiled the new CRANE tool during a San Francisco Climate Week (SFCW) panel discussion last week.
  • For climate-conscious impact investors who are interested in more than returns, the free, open-access tool will be an important resource to help assess the emissions impact potential of emerging climate technologies.
  • View the full release here: https://www.businesswire.com/news/home/20240501139862/en/
    Panelists listen to questions from the audience during the CRANE tool launch event.
  • (Photo: Business Wire)
    CRANE is the product of a partnership between Prime Coalition, a nonprofit on a mission to unlock catalytic capital and change the future of climate finance, and the Charlottesville, Virginia-based climate data science firm Rho Impact.

IperionX and Vegas Fastener to Co-Produce Titanium Fasteners for U.S. Army

Retrieved on: 
Wednesday, May 1, 2024
Defense, Natural Resources, Military, Contracts, Machinery, Machine Tools, Metalworking & Metallurgy, Mining, Minerals, Manufacturing, BAE, Newport News, Virginia, ASX, Partnership, Research, IPX, Growth, United States Navy, Titanium, Automation, Engineering, Steel, General Dynamics Electric Boat, General Dynamics, Corrosion, Robotics, Multimedia, Aircraft, Associate

IperionX Limited (NASDAQ: IPX, ASX: IPX) and Vegas Fastener Manufacturing, LLC (Vegas Fastener) have agreed to partner to develop and manufacture titanium alloy fasteners and precision components with IperionX’s advanced titanium products.

Key Points: 
  • IperionX Limited (NASDAQ: IPX, ASX: IPX) and Vegas Fastener Manufacturing, LLC (Vegas Fastener) have agreed to partner to develop and manufacture titanium alloy fasteners and precision components with IperionX’s advanced titanium products.
  • View the full release here: https://www.businesswire.com/news/home/20240501104505/en/
    Figure 1: High-performance fasteners manufactured by Vegas Fastener (Photo: Business Wire)
    Vegas Fastener, headquartered in Las Vegas, Nevada, is a global leader in the development and manufacturing of high-performance fasteners and custom machined components.
  • Vegas Fastener develops and manufactures precision high-performance fasteners using specialized alloys to meet demanding quality specifications.
  • The combined strengths and expertise of Vegas Fastener and IperionX will produce innovative solutions for customers and strengthen America’s manufacturing independence.”